XenaCare Holdings, Inc. announced today that its award winning over-the-counter (OTC) pain reliever, Cobroxin Advanced Topical Gel, is now available at Duane Reade drugstores located throughout metropolitan New York.
“Duane Reade is considered one of the premier and fastest growing retail pharmacies in the United States and consistently ranks top in the industry for productivity, as measured by sales per square foot,” explained Frank Rizzo, CEO of XenaCare Holdings. “We are excited to be working with the most recognized drugstore chain in New York City to introduce the Cobroxin Advanced Topical Gel to those suffering from moderate to severe chronic pain,” he added.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
About XenaCare Holdings
XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. In addition to Cobroxin, for the treatment of moderate to severe (Stage 2) chronic pain, the Company’s clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. In addition, the company offers formulations for the lifestyle performance market, which consists of a sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet as well as pharmacies. The company was founded in 2001 and is based in Delray Beach, Florida.
XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB: NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
